

***Fiscal Year 2024 Department of Defense/Defense Health Agency/Defense Medical Research and Development Program (DMRDP)  
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p><b>Psychedelic Treatment Research Clinical Trial Award</b></p> <p><b>Go to:</b></p> <ul style="list-style-type: none"> <li>• Program Announcement</li> <li>• General Application Instructions</li> </ul> <p><b>Grants.gov Funding Opportunity Number:</b> HT942524DMRDPTRCTA</p>	<p>Independent investigators at all career levels</p> <p>Eligibility limited to:</p> <ul style="list-style-type: none"> <li>• A department or agency of the federal government or a state government</li> <li>• An academic institution</li> <li>• A research foundation partnering with a federal government organization</li> </ul>	<ul style="list-style-type: none"> <li>• Applications must propose to address at least one of the two covered conditions (post-traumatic stress disorder and/or traumatic brain injury) and evaluate at least one of the following covered psychedelic substances: <ul style="list-style-type: none"> <li>- 3,4-Methylenedioxy-methamphetamine (commonly known as “MDMA”)</li> <li>- psilocybin</li> <li>- ibogaine</li> <li>- 5-Methoxy-N,N-dimethyltryptamine (commonly known as “5-MeO-DMT”)</li> <li>- plant-based alternative therapies</li> </ul> </li> <li>• An active-duty Service Member study population, which may include members of the reserve components, is required. Study populations other than Service Members will not be supported.</li> <li>• Treatment may involve the use of covered psychedelic substances alone or in conjunction with other evidence-based treatments.</li> <li>• Proposed projects may range from small proof-of-concept trials through large-scale trials to determine efficacy.</li> <li>• Inclusion of preliminary data relevant to the proposed clinical trial is required.</li> <li>• Department of Justice Drug Enforcement Agency application and licensure is required for work with controlled substances.</li> <li>• <b><i>Submission of a Letter of Intent is required prior to full application submission.</i></b></li> </ul>	<ul style="list-style-type: none"> <li>• Maximum funding of <b>\$4.9 million</b> for total costs (direct plus indirect costs)</li> <li>• Maximum period of performance is <b>3 years</b></li> </ul>	<p><b>Pre-Application (Letter of Intent):</b> September 20, 2024 5:00 p.m. Eastern time</p> <p><b>Application:</b> October 4, 2024 11:59 p.m. Eastern time</p>